|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
LHGDN |
[The expression of cathepsin-D in salivary adenoid cystic carcinoma].
|
11780226 |
2000 |
|
Adenoid Cystic Carcinoma
|
0.020 |
Biomarker
|
disease |
LHGDN |
[The expression of cathepsin-D in salivary adenoid cystic carcinoma].
|
11780226 |
2000 |
|
HER2 gene amplification
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Without excluding other molecular putative targets, we have focused our research on cathepsin D as a potential target, since it is often overexpressed in aggressive human breast cancers, including ER-negative tumors, and rarely associated with HER2-Neu amplification.
|
12790787 |
2003 |
|
Locally Recurrent Malignant Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
With regard to c-erbB-2, only its overexpression appeared to be significant for DFS and OS, although after multivariate analysis its prognostic power was weaker (P = 0.030 and P = 0.024 respectively). c-myc amplification and overexpression exhibited a tendency for locoregional recurrence (LRR) (P = 0.0024 and P = 0.0075 respectively), however, their prognostic value was lower after multivariate analysis and only CD remained significant.
|
10604737 |
1999 |
|
Parkinson Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
While PD-linked point mutant Vps35 D620N interacts with the cation-independent mannose-6-phosphate receptor (CI-M6PR), a known retromer cargo, we find that its expression disrupts the trafficking of cathepsin D, a CI-M6PR ligand and protease responsible for degradation of α-synuclein, a causative agent of PD.
|
24152121 |
2014 |
|
Sjogren's Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
Whereas cathepsin B immunopositivity was absent from glandular epithelial cells of healthy subjects and only slightly present in SS patients, cathepsin D immunoreactivity was considerably greater (p < 0.0001) in both the acini and the ducts of patients with SS as compared with control subjects.
|
11092531 |
2000 |
|
Barrett Epithelium
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
When compared with normal epithelium of NERD patients, (i) cathepsin D mRNA levels demonstrated a stepwise increase in expression (p<0.05) in erosive, metaplastic and EA tissue; (ii) AKR1B10 expression increased (p<0.05) 3- and 9-fold in erosive and Barrett's epithelium, respectively; and (iii) AKR1C2 levels increased (p<0.05) in erosive and Barrett's epithelium, but were reduced (p<0.05) in EA.
|
18396902 |
2008 |
|
Adenocarcinoma Of Esophagus
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
When compared with normal epithelium of NERD patients, (i) cathepsin D mRNA levels demonstrated a stepwise increase in expression (p<0.05) in erosive, metaplastic and EA tissue; (ii) AKR1B10 expression increased (p<0.05) 3- and 9-fold in erosive and Barrett's epithelium, respectively; and (iii) AKR1C2 levels increased (p<0.05) in erosive and Barrett's epithelium, but were reduced (p<0.05) in EA.
|
18396902 |
2008 |
|
Myocardial Infarction
|
0.030 |
Biomarker
|
disease |
BEFREE |
Western blot analyses revealed an increase in the precursor but not the mature form of CTSD in myocardial samples from explanted human failing hearts with ischemic heart disease, which is recapitulated in chronic myocardial infarction produced via coronary artery ligation in <i>Ctsd</i><sup>+/+</sup> but not <i>Ctsd</i><sup>
|
28694354 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We used northern blot analysis of RNA from fresh-frozen tumour specimens to study the patterns of expression of genes for proteolytic enzymes (cysteine proteinase cathepsin L and aspartyl proteinase cathepsin D; matrix metalloproteinases MMP-9 and MMP-2), tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2, and TP53.
|
9643688 |
1998 |
|
melanoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
We used a bioinformatics approach to assess the impact of amino acid (AA) substitutions on the sensitivity of CECMPs to proteases relevant to melanoma and on the binding affinities for HLA class I. CECMP peptides with AA substitutions overwhelmingly reflect increased sensitivity to proteases implicated in melanoma development (MME, CTSS, MMP2, CTSD, CTSL) in comparison to the wild-type peptide sequences.
|
29047110 |
2018 |
|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
We show that HIF-1 regulates the expression of genes encoding cathepsin D; matrix metalloproteinase 2; urokinase plasminogen activator receptor (uPAR); fibronectin 1; keratins 14, 18, and 19; vimentin; transforming growth factor alpha; and autocrine motility factor, which are proteins that play established roles in the pathophysiology of invasion.
|
12615733 |
2003 |
|
Carcinogenesis
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
We investigated whether stromal cathepsin D (CathD) overexpression affects prostate tumorigenesis through a paracrine mechanism.
|
22996917 |
2013 |
|
Frontotemporal Lobar Degeneration
|
0.010 |
Biomarker
|
disease |
BEFREE |
We investigated changes in the degradative pathways in 60 patients with different pathological or genetic forms of FTLD employing immunohistochemistry for marker proteins such as lysosomal-associated membrane proteins 1 (LAMP-1) and 2 (LAMP-2), cathepsin D (CTSD) and microtubule-associated protein 1 light chain 3 alpha (LC3A).
|
29790198 |
2019 |
|
Pancreatic carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We identified 145 differentially secreted proteins (>1.5-fold change), several of which were previously reported as either up-regulated (e.g. cathepsin D, macrophage colony stimulation factor, and fibronectin receptor) or down-regulated (e.g. profilin 1 and IGFBP-7) proteins in pancreatic cancer, confirming the validity of our approach.
|
16215274 |
2006 |
|
Malignant neoplasm of pancreas
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We identified 145 differentially secreted proteins (>1.5-fold change), several of which were previously reported as either up-regulated (e.g. cathepsin D, macrophage colony stimulation factor, and fibronectin receptor) or down-regulated (e.g. profilin 1 and IGFBP-7) proteins in pancreatic cancer, confirming the validity of our approach.
|
16215274 |
2006 |
|
Keloid
|
0.010 |
Biomarker
|
disease |
BEFREE |
We hypothesized that cathepsin B (cathB), cathepsin D (cathD) and cathepsin G (cathG) are present within the ESC-like population in KLs and contribute to bypass loops of the RAS.
|
31524804 |
2019 |
|
Colon Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
We have studied the intracellular trafficking of cathepsin D in different colon carcinoma cell populations: the HT-29 cell line, composed of >95% undifferentiated cells; 2 subpopulations derived from this cell line, containing cells committed to differentiation into mucin-secreting cells (HT-29 MTX) or enterocyte-like cells (HT-29 G-) after confluence; and the Caco-2 cell line, which spontaneously differentiates into enterocyte-like cells after confluence.
|
8945619 |
1996 |
|
Juvenile Neuronal Ceroid Lipofuscinosis
|
0.210 |
GeneticVariation
|
disease |
BEFREE |
We have shown recently that the targeted deletion of the pro-apoptotic molecule Bax prevents apoptotic markers but not neuron death and neurodegeneration induced by CD deficiency, which suggests that alterations in the macroautophagy-lysosomal degradation pathway can mediate neuron death in NCL/Batten Disease in the absence of apoptosis.
|
17495518 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We have compared by RNA in situ hybridisation on serial cryo-sections the distribution of cathepsin D (cathD), stromelysin 3 (strom-3), and urokinase plasminogen activator (UPA) gene expression in different tissues of human benign and malignant mammary tumors.
|
8861840 |
1996 |
|
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found that the 8-month-old AD animals presented significantly higher deposition of Aβ(1-42) and expression of TFEB and its targeted proteins, such as LAMP-1 and cathepsin D, and autophagy-associated LC3-II and p62 in brain tissues than in others.
|
26368054 |
2015 |
|
Melanocytic nevus
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We found that cathepsin D was expressed in all of the dysplastic nevi and primary and metastatic melanomas tested but in only 18% of nevocellular nevi (five of 27), whereas normal melanocytes showed no cathepsin D expression.
|
7860998 |
1995 |
|
Dysplastic Nevus
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
We found that cathepsin D was expressed in all of the dysplastic nevi and primary and metastatic melanomas tested but in only 18% of nevocellular nevi (five of 27), whereas normal melanocytes showed no cathepsin D expression.
|
7860998 |
1995 |
|
Psoriatic plaque
|
0.010 |
Biomarker
|
disease |
BEFREE |
We found cathepsin D and zinc-alpha(2)-glycoprotein, two catalytic enzymes associated with apoptosis and desquamation, to be present in the stratum corneum of the normal epidermis but absent from the psoriatic plaque.
|
10698972 |
2000 |
|
Alkalemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We demonstrated that exposure of microglia to this cART cocktail induced lysosomal membrane permeabilization (LMP), which subsequently resulted in impaired lysosomal functioning involving elevated pH and decreased cathepsin D (CTSD) activity. cART exposure of microglia resulted in increased formation of autophagosomes as demonstrated by a time-dependent increase of autophagy markers, with a concomitant defect in the fusion of the lysosomes with the autophagosome.
|
31569373 |
2019 |